Arovella Strengthens Cash Position with AU$3.21 million R&D Rebate

Arovella Therapeutics Ltd (ASX: ALA) has boosted its financial position with the receipt of an AU$3.21 million R&D Tax Incentive refund for FY2025. The rebate, provided under the Australian Government’s Research and Development Tax Incentive program, will support the company’s ongoing efforts to advance its lead cell therapy asset, ALA-101. This program provides eligible companies with refunds covering 43.5% to 48.5% of qualifying R&D expenditure, making it an important source of non-dilutive funding for innovative biotech firms.

Arovella’s CEO and Managing Director, Dr. Michael Baker, highlighted that with these funds, the company is well placed to progress ALA-101 into first-in-human clinical trials targeting CD19-positive lymphoma and leukaemia. He also confirmed that Arovella plans to lodge its IND application within this calendar year, paving the way for the FDA to accept it and trial commencement to follow soon after. This development reinforces the company’s ability to advance its pipeline with greater financial flexibility.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com